NCT02829541View on ClinicalTrials.gov

A Phase 1, Single-Ascending-Dose, Safety, Tolerability, Pharmacokinetic(PK), and Pharmacodynamic(PD) Study of BIIB068 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2016

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Systemic Lupos Erythematosus, SLE
Interventions
DRUG

BIIB068

Administered as specified in the treatment arm.

DRUG

Placebo

Administered as specified in the treatment arm

Trial Locations (1)

47710

Research Site, Evansville

Sponsors

Lead Sponsor

Biogen
All Listed Sponsors
lead

Biogen

INDUSTRY